Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Realm Thera. LSE:RLM London Ordinary Share GB00B3XBCR18 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 7.70p 7.40p 8.00p 7.70p 7.70p 7.70p 100,478 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.8 -7.8 -11.8 - 10.60

Realm Thera. Share Discussion Threads

Showing 51 to 69 of 75 messages
Chat Pages: 3  2  1
DateSubjectAuthorDiscuss
29/11/2018
08:07
A bidding war gives a company in this positions options and the upper hand in negogiations. No wonder 81% of the stock with significant holders were happy to hold in UK & no wonder 1.3m of just 4.6m shares in issue have recently been taken up by II's on Nasdaq
colin12345678
29/11/2018
08:07
multiple offers and still sub cash.
colin12345678
29/11/2018
08:03
As part of the strategic review, Realm received multiple indications of interest which include a potential sale of the Company, contemplated as a reverse merger
colin12345678
28/11/2018
11:37
Probs 18-20p offer
the stinger
28/11/2018
11:17
I wonder if we'll get an announcement at the end of the week. That's when the time is up for indicative offers.
arthur_lame_stocks
01/10/2018
20:12
A_L_S I can well understand why you did what you did given that as per my calculations Marcap is approx £10.5m and June cash minus current liabilities is a bit over £15m. I sold out August 14/15. I do not see their IP being worth much and have no feel for how much their tax losses are worth. I doubt if you will loose money especially as the big shareholders will want a speedy resolution but do not see myself joining you.
cerrito
26/9/2018
16:41
Well I had a small punt on these today based on the cash burn dropping dramatically so that the discount to cash is not quickly eaten up and there being some further value in the IP and accumulated losses (which are very large). Not a big punt, just some fun money as it could all go wrong.
arthur_lame_stocks
15/8/2018
08:32
AIM:RLM - "Review underway after Atopic Dermatitis miss" RLM’s randomised, double-blind, placebo controlled, Phase II clinical trial, PR022 showed no difference from vehicle in the primary endpoint of percentage change in Eczema Area Severity Index (EASI) versus baseline. The Company is now analysing the data to interpret the top-line result, as well as the other data collected in the study. The conclusions of this review will be used to inform decision-making going forward, and this includes evaluating the implications of these data for RLM’s preclinical HOCl dermatology pipeline in Acne and Psoriasis – both of which had been making good progress. RLM indicates that it will also review the possibility of acquiring one or more new assets, although no specific detail is available. They expect to disclose the outcome of the review in September. Pending the outcome of the review, we are suspending our forecasts and valuation that we can update when the Group’s strategic direction becomes clearer in September. In the meantime, RLM has the benefit of significant cash on the balance sheet, an experienced Executive team, and substantial IP filed. Read the full note here ... https://www.equitydevelopment.co.uk/edreader/?d=%3D%3DAO1QjM
edmonda
14/8/2018
22:32
Looking at what support their cash pile can give the share price They have 116 m shares and at the end of June US23m. Cash burn in H1 was US10m, including the NASDAQ listing costs. I am assuming they have reduced R&D on acne/ psioriasis to the minimum until next month when they make their review. At the end of Sept cash/ cash equivalents I estimate will be Us20m approx or approx 13.5p per share. Of course in the extremely unlikely event that they were to liquidate the company this cash balance would go down to say 11p a share after the costs of liquidation offset by the sale of their IP. PS Went on to the Nasdaq webpage to see what RLM did there but said price unchanged at $0 and no trades so perhaps RLM not live on NASDAQ yet.
cerrito
14/8/2018
13:36
Nothing new in the conference call. Just said what they said in the RNS that the information given was hot off the press and that need to digest it and in September there will be an update with how they will proceed with PRO22/AD as well as the acne and psioriasis programme or indeed buying some of the other assets they are looking at. They do have US23m in cash/equivalents and will not have the repeat of the US 1.5 m spent on the NASDAQ listing which will be enough to take the acne and psioriasis programme a good way forward. Rather kicking myself for not asking him how the scientists say this AD result affects their view of how the acne and/or psioriasis results will work out. I need to decide what to do with the fat end that I have PS Not speaking at the conference this afternoon
cerrito
14/8/2018
12:37
Realm Therapeutics (RLM) News Out Just Now http://crweworld.com/article/news-provided-by-pr-newswire/771725/realm-therapeutics-reports-top-line-data-from-phase-2-trial-of-pr022-in-atopic-dermatitis-and-first-half-2018-financial-results
danieldanj
14/8/2018
10:21
I also substantially reduced my exposure this morning and indeed am surprised that the price had not fallen further. Am planning to listen to the conference call.
cerrito
14/8/2018
07:49
What a basket case this has become - what's that two failed trials now since flotation. They tried to play it down in the RNS but market not having it. My small position (now even smaller) has been chopped now
davr0s
10/7/2018
08:38
Does anyone know what to make of this morning's RNS in which 22 is compared to an arthritis solution? Good to hear that top line readout still on track for September.
cerrito
09/7/2018
21:16
My eye caught this report on a Singapore company doing an AD Phase 1 with some interesting industry background. https://www.edisoninvestmentresearch.com/research/report/aslan-pharmaceuticals575663/full
cerrito
24/5/2018
08:18
as per name of thread : after today's encouraging news on enrollment completed for Phase II trial, updated ED research note just published. Freely accessible here: https://www.equitydevelopment.co.uk/edreader/?ltkn=[ID]&d=%3D%3DANyQjM
edmonda
29/3/2018
20:44
New realm thread with charts and information
haroldthegreat
12/3/2018
12:24
Disappointing and rather surprising news this morning and it will be interesting to see Martin's webcast presentation at the Cowen conference tomorrow. Had not expected abondonment so soon; of course 13 had less financial potential than 22 and what they said today that there is no crossover between 13 and 22 is that the prospects for 22 are unchanged with this news reflects my previous understanding. This will mean I assume that they will have finance to progress 22 that much further. I am assuming that 13 dry eye which is in preclinical is not affected; note no mention perhaps means that not regarded as important. One downer is that 13 was ahead of 22 so if things had gone without a hitch would have generated revenue sooner. Pleasantly surprised that there has been so much liquidity and have lightened up a bit.
cerrito
15/2/2018
10:33
Positive clinical and business update released today and new research note with valuation update now out from Equity Dev. Free access here: https://www.equitydevelopment.co.uk/company/?company=Realm+Therapeutics&c=xUTO … AND you can see the CEO of Realm present at the next ED Private Investor Forum in London on Wed 28 March, register here: https://www.eventbrite.co.uk/e/equity-development-investor-forum-march-2018-tickets-43192146874?ref=elink
edmonda
Chat Pages: 3  2  1
Your Recent History
LSE
RLM
Realm Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181210 17:51:29